A Feasibility Study of a Suicide Prevention Video

November 3, 2021 updated by: Fraser Health

A Pilot Study of the Effectiveness of a Suicide Prevention Video Tool to Reduce the Incidence of Active Suicide Behavior in Individuals With Psychiatric Illness

This initial study is a pilot feasibility study with a primary objective of assessing the feasibility of a larger study by evaluating the procedures and methodology, as well as collecting pilot data. The eventual research goal is to demonstrate whether a suicide prevention video in addition to standard care for suicidality is an effective strategy to reduce suicidal behaviours in individuals with a history of such. The suicide prevention video is developed as an educational tool to inform participants of the various consequences of suicide as well as giving a message of hope. It is hoped that such an approach will help to reduce future suicidal behaviours in those who have a history of such. If so, then this could be made as a part of the standard of care in treating patients with suicidality.

Study Overview

Detailed Description

This pilot study will assess the study procedures and methodology to determine the feasibility of a larger study that will be done to asses for any difference in suicidal behaviours when the suicide prevention video is used in addition to standard of care. As such, the primary objectives will include:

  • Testing of recruitment, retention, consent, and assignment procedures
  • Validating the inclusion/exclusion criteria
  • Determining the acceptability and safety of the proposed intervention
  • Evaluating implementation procedures and methodology for the intervention
  • Evaluating the appropriateness of timing and frequency of data collection points
  • Evaluating the appropriateness and feasibility of the assessment tools
  • Obtaining parameters for sample size estimation for the larger study
  • Assessing the effectiveness of the video medium, content in the video and length of the video

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • British Columbia
      • New Westminster, British Columbia, Canada
        • Royal Columbian and Eagle Ridge Hospitals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 19 years or older
  • Admitted to the Royal Columbian Hospital under psychiatric services
  • Individuals will have had suicidal behaviours as part of their presentation leading to hospitalization
  • Individuals must be at the level 2 observation privileges or higher
  • Individuals must be capable of giving consent to participate in the study
  • Individuals must speak and read English fluently Individuals admitted to the hospital as voluntary and involuntary (certified) patients

Exclusion Criteria:

  • Individuals with hearing or visual deficits that impairs hearing or viewing the SPV
  • Individuals who are under the influence of drugs, such as intoxication or active withdrawal
  • Individuals with established diagnoses of cognitive impairment affecting their ability to give consent, understand what is expected of them in the study or follow directions
  • Patients that require a substitute decision makers to provide consent
  • Individuals whose behaviors an/or cognition are actively affected by ongoing psychosis, including hallucinations, delusions, and disorganized behaviors
  • Individuals whose treating team assess them as likely to have a negative response to the SPV, for example paranoia around electronic devices
  • Patient's who's attending physiatrist is one of the study team members
  • Patients who are currently under the direct care of any of the investigators Patients that had acute suicidality in the last 24 hours

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Suicide prevention video
In this group, in addition to receiving the standard of care for their suicidality, the participants will also view a suicide prevention video.
The video has been developed by the research team as an educational tool to teach patients about suicide, the consequences of such and imparting a message of hope.
The standard suicide treatment will be determine by the attending physician and can include medications and/or psychotherapy
ACTIVE_COMPARATOR: Standard suicide treatment
In this group, participants will only receive the standard of care for their suicidality, which can include medications and/or therapy. The care will be determine by their attending physician.
The standard suicide treatment will be determine by the attending physician and can include medications and/or psychotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
An assessment of suicidal behaviours following the use of a video intervention
Time Frame: 12 months
To assess the change in suicidality of patients admitted for such using the Modified Scale for Suicidal Ideation after being given an educational video explaining common misinformation about suicide.
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean change from baseline in the expression of suicidal ideation on the Modified Scale for Suicidal Ideation at 48 hours, 3 months and 6 months
Time Frame: 12 months
To measure the change in suicidal behaviours after viewing the video using the "The Modified Scale for Suicidal Ideation". The scale is used to assess the presence or absence of suicide ideation and the degree of severity of suicidal ideas. The benefit of this scale is that it was developed so that paraprofessionals could administer the scale, yet demonstrated excellent internal consistency and interrater reliability, correlated highly with clinician's ratings of suicidal ideation and risk, and discriminated between suicide attempters and nonattempters prior to hospitalization. The scale would be administered at baseline, after watching the video and at 3 and 6 months after watching the video. Each question is scored for a total score that is interpreted as degree of suicidal ideation. Total score range is 0 to 54. Higher scores indicate more severe suicidal ideations. Changes in the total scores will be analyzed.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Hem Phaterpekar, MD, Fraser Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2017

Primary Completion (ACTUAL)

June 1, 2020

Study Completion (ACTUAL)

June 1, 2020

Study Registration Dates

First Submitted

August 23, 2016

First Submitted That Met QC Criteria

November 3, 2021

First Posted (ACTUAL)

November 15, 2021

Study Record Updates

Last Update Posted (ACTUAL)

November 15, 2021

Last Update Submitted That Met QC Criteria

November 3, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • FHREB 2015-141

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe